IMU-838 trials for PSC and Coronavirus

interesting news, though very early of course.
“ Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients…
Furthermore, Immunic’s collaboration partner, the Mayo Clinic, has started an investigator-sponsored proof-of-concept clinical trial testing IMU-838 activity in patients with primary sclerosing cholangitis.”

I wouldn’t mind to have one treatment to cure both PSC and Coronavirus…

Let’s cross our fingers.